Please login to the form below

Not currently logged in
Email:
Password:

Biovitrum

This page shows the latest Biovitrum news and features for those working in and with pharma, biotech and healthcare.

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Hopes to boost haematology franchise with lead drug Doptelet. Dova Pharmaceuticals is set to be acquired by Swedish Orphan Biovitrum AB (Sobi) for up to $915m, dependent on the regulatory approval

Latest news

More from news
Approximately 4 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    Orphan Biovitrum) a company that, as its name suggests, is entirely dedicated to rare conditions.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    49. †Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum.  Development, supply and commercialisation. Xiapex (collagenase clostridium histolyticum) (approved)  .  40. All deals are worldwide unless otherwise noted – see below:.   .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 7 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics